Lexeo reports interim data for heart condition gene therapy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/2/2026
- Wall St set to open higher after June jobs report eases rate hike bets
- Oil falls to four-month low as US, Iran conclude talks in Doha
- Bond prices and stocks rally on softer payrolls, dollar falls
- Meta Platforms stock surges 8% on cloud business plans
- Humanoid robot component stocks surge on supply-chain optimism
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy
January 12, 2026 7:00 AM ESTLX2020 generally well tolerated across ten participants with no clinically significant complement activationÂ
LX2020 transduction, transcription, and increased protein expression observed across participants with dose-dependent response; mean increase in PKP2 protein of 93% in low-dose cohort and 162% in high-dose cohorts
Arrhythmia burden stabilized or improved in majority of participants with dose-dependent response in non-sustained ventricular tachycardia and premature ventricular contractions
Company to host webcast today at 8:00 AM ET / 5:00 AM PT
NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) --... More
